ASCO Guidelines 2022

Updated ASCO Guidelines strongly recommend use of the Oncotype DX Breast Recurrence Score® Test in node-negative and the majority of node-positive early-stage breast cancer patients. 
ASCO is a trademark of the American Society of Clinical Oncology. 
ASCO does not endorse any product or therapy.

Landmark RxPONDER Trial Results

Publication in The New England Journal of Medicine confirms that tens of thousands of women with node-positive, early-stage breast cancer can avoid chemotherapy with the Oncotype DX® test.
Making cancer care smarter.™